Following approval from the British health regulator for Eli Lilly's new weight-loss treatment, Health Secretary Steve Barclay expressed optimism about the potential benefits for thousands of
obese individuals in the UK. The drug, Zepbound (also known as Mounjaro or tirzepatide), received the green light from both U.S. and UK regulators, offering a formidable competitor to Novo Nordisk's Wegovy in addressing rising obesity rates.
In a statement, Barclay highlighted the drug's potential to assist people struggling with obesity and alleviate weight-related health issues when combined with proper diet and physical activity. He emphasized the impact on reducing waiting lists and potential cost savings for the National Health Service (NHS).
However, Barclay noted that additional approvals were necessary before the drug could be included in NHS coverage.
